Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
| Revenue (TTM) | $4.00B |
| Gross Profit (TTM) | $1.38B |
| EBITDA | $849.12M |
| Operating Margin | 15.10% |
| Return on Equity | -7.52% |
| Return on Assets | 4.11% |
| Revenue/Share (TTM) | $81.86 |
| Book Value | $59.50 |
| Price-to-Book | 4.71 |
| Price-to-Sales (TTM) | 3.45 |
| EV/Revenue | 4.052 |
| EV/EBITDA | 73.50 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | -2.70% |
| Shares Outstanding | $48.17M |
| Float | $47.22M |
| % Insiders | 0.47% |
| % Institutions | 123.00% |
Volatility is currently expanding
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and a positive inflection in order trends. CRL raised guidance, now expecting slightly positive organic growth and EPS of $11.15–$11.45, with margin expansion locked in through divestitures and cost cuts. Segment performance is mixed: DSA shows strong backlog and book-to-bill, while RMS faces U.S. weakness offset by China strength; manufacturing margins benefit from divestitures.
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River Laboratories (CRL) came out with quarterly earnings of $3.02 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $3.12 per share a year ago.
CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRL and any ticker you trade — then tracks every position and per-strategy win rate.
